Walleye Capital LLC Sage Therapeutics, Inc. Call Options Transaction History

Walleye Capital LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $118,638 - $221,052	-16,900 Reduced 69.26%	7,500 $54,000
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $231,702 - $392,009	21,900 Added 876.0%	24,400 $264,000
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $243,922 - $353,045	-13,100 Reduced 83.97%	2,500 $46,000
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $117,990 - $153,594	6,900 Added 79.31%	15,600 $338,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $88,775 - $259,593	5,300 Added 155.88%	8,700 $179,000
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $138,210 - $202,436	3,400 New	3,400 $159,000
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $3,220 - $4,361	100 Added 2.86%	3,600 $137,000
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $112,980 - $151,445	3,500 New	3,500 $137,000
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $2.27 Million - $5.85 Million	-37,800 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $5.09 Million - $6.9 Million	36,300 Added 2420.0%	37,800 $5.3 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $236,775 - $274,635	1,500 New	1,500 $275,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $342M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.